Metal organic framework-based antithrombotic surfaces

基于金属有机骨架的抗血栓表面

基本信息

  • 批准号:
    10155583
  • 负责人:
  • 金额:
    $ 35.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-05-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT: Each year billions of health care dollars are spent on medical devices that fail in clinical practice. These device failures occur over various timescales of the devices due to multiple factors including thrombosis, inflammation, infection, and tissue overgrowth on the surface of the implanted device as well as mechanical device failures. Over the last 50 years, much has been learned about these device failures resulting in attempts to prevent failures using (1) alternative systemic drug therapies, (2) surface modifications on the device, or (3) a combination of both approaches. Despite efforts to improve the efficacy of blood-contacting and implantable medical devices, the incompatibility of these materials within human blood and tissue still causes serious complications in patients. Thus, systemic or regional drug therapies such as heparin remain necessary. As a result, strategies that can leverage the biological properties of naturally occurring bioagents such as nitric oxide (NO) have clear implications for a wide variety of medical devices. These materials offer localized control of platelets at the blood-material interface where bioactivity is targeted. The research strategy detailed here in focuses on developing materials that can produce NO from endogenous sources for extended periods of time and will overcome the fundamental limitations of current NO materials. Using metal organic frameworks (MOFs) as NO catalysts, device coatings will now be able to (1) produce NO for longer time period than ever achieved to date and (2) allow systematic modification while maintaining the structural properties that make them suitable for clinical applications. The principal premise of this project proposal is to utilize the inherent structural features of MOF materials to develop physiologically-relevant NO catalysts for use in catheter coatings. As a part of this grant, MOFs will be prepared, blended into catheter coatings and rigorously tested for their long- term function and mechanical properties, evaluated for safety via toxicity studies and characterized by an array of in vitro bioassays. Final catheter prototypes will be tested in a rabbit model for their anti-thrombotic properties at time points beyond the capabilities of current technologies.
文摘:

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Computational Insights into the Mechanism of Nitric Oxide Generation from S-Nitrosoglutathione Catalyzed by a Copper Metal-Organic Framework.
  • DOI:
    10.1021/jacs.3c01569
  • 发表时间:
    2023-05
  • 期刊:
  • 影响因子:
    15
  • 作者:
    Benjamin J G Rousseau;A. Soudackov;Robert R. Tuttle;Melissa M. Reynolds;R. Finke;S. Hammes‐Schiffer
  • 通讯作者:
    Benjamin J G Rousseau;A. Soudackov;Robert R. Tuttle;Melissa M. Reynolds;R. Finke;S. Hammes‐Schiffer
Nitric Oxide-Releasing Emulsion with Hyaluronic Acid and Vitamin E.
含有透明质酸和维生素 E 的一氧化氮释放乳液。
  • DOI:
    10.1039/c9ra03840j
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Yapor,JanetP;Gordon,JennaL;Henderson,ChristinaN;Reynolds,MelissaM
  • 通讯作者:
    Reynolds,MelissaM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hitesh Handa其他文献

Hitesh Handa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hitesh Handa', 18)}}的其他基金

Metal organic framework-based antithrombotic surfaces
基于金属有机骨架的抗血栓表面
  • 批准号:
    9922365
  • 财政年份:
    2018
  • 资助金额:
    $ 35.95万
  • 项目类别:
Engineering nitric oxide releasing polymer with immobilized thrombin inhibitor for blood contacting applications
工程化一氧化氮释放聚合物与固定凝血酶抑制剂用于血液接触应用
  • 批准号:
    10545010
  • 财政年份:
    2017
  • 资助金额:
    $ 35.95万
  • 项目类别:
Engineering nitric oxide releasing polymer with immobilized thrombin inhibitor for blood contacting applications
工程化一氧化氮释放聚合物与固定凝血酶抑制剂用于血液接触应用
  • 批准号:
    9883033
  • 财政年份:
    2017
  • 资助金额:
    $ 35.95万
  • 项目类别:
Engineering nitric oxide releasing polymer with immobilized thrombin inhibitor for blood contacting applications
工程化一氧化氮释放聚合物与固定凝血酶抑制剂用于血液接触应用
  • 批准号:
    10367198
  • 财政年份:
    2017
  • 资助金额:
    $ 35.95万
  • 项目类别:
Prevention of Thrombosis by NO Secreting Polymers
通过分泌 NO 的聚合物预防血栓形成
  • 批准号:
    8522219
  • 财政年份:
    2012
  • 资助金额:
    $ 35.95万
  • 项目类别:
prevention of thrombosis by NO secreting polymer
NO分泌聚合物预防血栓形成
  • 批准号:
    9067509
  • 财政年份:
    2012
  • 资助金额:
    $ 35.95万
  • 项目类别:
Prevention of Thrombosis by NO Secreting Polymers
通过分泌 NO 的聚合物预防血栓形成
  • 批准号:
    8383118
  • 财政年份:
    2012
  • 资助金额:
    $ 35.95万
  • 项目类别:
Prevention of Thrombosis by NO Secreting Polymers
通过分泌 NO 的聚合物预防血栓形成
  • 批准号:
    8703168
  • 财政年份:
    2012
  • 资助金额:
    $ 35.95万
  • 项目类别:
Stent Coating to Prevent Restenosis and Subacute Thrombosis
支架涂层可预防再狭窄和亚急性血栓形成
  • 批准号:
    7682096
  • 财政年份:
    2008
  • 资助金额:
    $ 35.95万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 35.95万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了